Russell Investments Group Ltd. Sells 15,560 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Russell Investments Group Ltd. decreased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 52.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,281 shares of the company’s stock after selling 15,560 shares during the quarter. Russell Investments Group Ltd.’s holdings in Mirum Pharmaceuticals were worth $343,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of MIRM. Raymond James Financial Services Advisors Inc. increased its position in shares of Mirum Pharmaceuticals by 110.5% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 53,301 shares of the company’s stock valued at $1,174,000 after acquiring an additional 27,979 shares during the period. Panagora Asset Management Inc. grew its position in shares of Mirum Pharmaceuticals by 3.6% in the 1st quarter. Panagora Asset Management Inc. now owns 69,486 shares of the company’s stock worth $1,530,000 after buying an additional 2,427 shares during the last quarter. BlackRock Inc. grew its position in shares of Mirum Pharmaceuticals by 1.4% in the 1st quarter. BlackRock Inc. now owns 782,830 shares of the company’s stock worth $17,238,000 after buying an additional 10,732 shares during the last quarter. Federated Hermes Inc. bought a new stake in shares of Mirum Pharmaceuticals in the 1st quarter worth approximately $440,000. Finally, Prudential Financial Inc. grew its position in shares of Mirum Pharmaceuticals by 25.4% in the 1st quarter. Prudential Financial Inc. now owns 80,300 shares of the company’s stock worth $1,768,000 after buying an additional 16,270 shares during the last quarter.

Mirum Pharmaceuticals Stock Up 0.0 %

NASDAQ:MIRM opened at $26.44 on Tuesday. The firm’s 50-day moving average price is $25.90 and its 200-day moving average price is $25.67. The company has a market capitalization of $1.01 billion, a PE ratio of -5.57 and a beta of 1.25. The company has a debt-to-equity ratio of 3.89, a current ratio of 6.59 and a quick ratio of 6.44. Mirum Pharmaceuticals, Inc. has a 1-year low of $17.32 and a 1-year high of $30.39.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.11). Mirum Pharmaceuticals had a negative return on equity of 103.59% and a negative net margin of 152.27%. The company had revenue of $37.50 million during the quarter, compared to the consensus estimate of $30.00 million. On average, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -2.41 EPS for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 5,498 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $25.65, for a total value of $141,023.70. Following the completion of the transaction, the chief executive officer now owns 115,334 shares of the company’s stock, valued at approximately $2,958,317.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO Christopher Peetz sold 5,498 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $25.65, for a total transaction of $141,023.70. Following the completion of the sale, the chief executive officer now owns 115,334 shares of the company’s stock, valued at $2,958,317.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jolanda Howe sold 3,459 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $26.23, for a total transaction of $90,729.57. The disclosure for this sale can be found here. Insiders have sold a total of 12,301 shares of company stock valued at $317,527 in the last ninety days. 24.06% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MIRM. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 target price on shares of Mirum Pharmaceuticals in a research report on Friday, August 4th. Raymond James raised their target price on shares of Mirum Pharmaceuticals from $79.00 to $84.00 and gave the stock a “strong-buy” rating in a research report on Monday, August 21st.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.